NCT01508104View on ClinicalTrials.gov

Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

December 31, 2014

Conditions
Cancer
Interventions
DRUG

BEZ235

dose escalation 400mg- 1000mg per day

DRUG

Everolimus

dose escalation 2.5 to 5 mg per day

Trial Locations (1)

45267-0502

University of Cincinnati, Cincinnati

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

University of Cincinnati

OTHER